Literature DB >> 18816806

Treating children with acute lymphoblastic leukemia and Down syndrome: pharmacokinetics provides insight into vincristine therapy.

Clinton F Stewart1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 18816806      PMCID： PMC2585145          DOI： 10.1002/pbc.21743

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


× No keyword cloud information.
  10 in total

Review 1.  A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples.

Authors:  Robert J Bauer; Serge Guzy; Chee Ng
Journal:  AAPS J       Date:  2007-03-02       Impact factor: 4.009

Review 2.  Down syndrome and acute lymphoblastic leukaemia.

Authors:  James A Whitlock
Journal:  Br J Haematol       Date:  2006-10-10       Impact factor: 6.998

3.  Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study.

Authors:  James A Whitlock; Harland N Sather; Paul Gaynon; Leslie L Robison; Robert J Wells; Michael Trigg; Nyla A Heerema; Smita Bhatia
Journal:  Blood       Date:  2005-08-18       Impact factor: 22.113

4.  Vincristine in childhood leukaemia: no pharmacokinetic rationale for dose reduction in adolescents.

Authors:  B M Frost; G Lönnerholm; P Koopmans; J Abrahamsson; M Behrendtz; A Castor; E Forestier; D R A Uges; S S N de Graaf
Journal:  Acta Paediatr       Date:  2003-05       Impact factor: 2.299

5.  Vincristine pharmacokinetics is related to clinical outcome in children with standard risk acute lymphoblastic leukemia.

Authors:  Gudmar Lönnerholm; Britt-Marie Frost; Jonas Abrahamsson; Mikael Behrendtz; Anders Castor; Erik Forestier; Mats Heyman; Donald R A Uges; Siebold S N de Graaf
Journal:  Br J Haematol       Date:  2008-06-04       Impact factor: 6.998

6.  Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia.

Authors:  W R Crom; S S de Graaf; T Synold; D R Uges; H Bloemhof; G Rivera; M L Christensen; H Mahmoud; W E Evans
Journal:  J Pediatr       Date:  1994-10       Impact factor: 4.406

7.  Vincristine pharmacokinetics in children with Down syndrome.

Authors:  Gudmar Lönnerholm; Britt-Marie Frost; Stefan Söderhäll; Siebold S N de Graaf
Journal:  Pediatr Blood Cancer       Date:  2009-01       Impact factor: 3.167

8.  Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia.

Authors:  M L Garré; M V Relling; D Kalwinsky; R Dodge; W R Crom; M Abromowitch; C H Pui; W E Evans
Journal:  J Pediatr       Date:  1987-10       Impact factor: 4.406

9.  Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952.

Authors:  Mylène Bassal; Mei K La; James A Whitlock; Harland N Sather; Nyla A Heerema; Paul S Gaynon; Linda C Stork
Journal:  Pediatr Blood Cancer       Date:  2005-01       Impact factor: 3.167

Review 10.  Acute leukemias in children with Down syndrome.

Authors:  Michel C Zwaan; Dirk Reinhardt; Johann Hitzler; Paresh Vyas
Journal:  Pediatr Clin North Am       Date:  2008-02       Impact factor: 3.278
  10 in total
  1 in total

Review 1.  Pharmacokinetics of Chemotherapeutic Drugs in Pediatric Patients With Down Syndrome and Leukemia.

Authors:  Erik Hefti; Javier G Blanco
Journal:  J Pediatr Hematol Oncol       Date:  2016-05       Impact factor: 1.289
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.